Discover
STOK
Stoke Therapeutics, Inc.
32.71
2 x 24.02
2 x 41.19
bid
ask
-
0.01
0.03%
2 @ 04:00 PM
31.76 -0.95 (2.90%)
| Ytd | 3.06% | |
| 1y | 180.77% |
32.09
day range
33.50
11.31
52 week range
40.22
| Open | 32.63 | Prev Close | 32.72 | Low | 32.09 | High | 33.50 | Mkt Cap | 2.04B |
| Vol | 1.17M | Avg Vol | 692.18K | EPS | -2.86 | P/E | N/A | Forward P/E | -10.54 |
| Beta | 1.19 | Short Ratio | 20.80 | Inst. Own | 119.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 31.43 | 200-d Avg | 31.13 | 1yr Est | 45.10 |
STOK News
benzinga.com
Stoke Therapeutics Completes Enrollment Of 162 Patients Into Phase 3 EMPEROR Study Of Zorevunersen;
—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027——Ph
businesswire.com
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company